All In Biotech

Drug Trial Radar · NCT05248893

A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

A Phase 3, Multicenter, Open-label Study to Evaluate the Safety of AGN-151586 for the Treatment of Glabellar Lines

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

992

Actual

Start

Feb 25, 2022

Primary completion

Jun 26, 2023

Study completion Jun 26, 2023

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with botulinum toxin. The primary purpose of this study is to evaluate the safety of AGN-151586 over up to three treatments of the study drug to improve the appearance of glabellar lines. AGN-151586 is an investigational product being developed for the treatment of GL. Around 940 to 1100 adult participants with moderate to severe GL will be enrolled in the study in approximately 45 sites in the United States. This is an open-label study in which all participants will receive 5 intramuscular AGN-151586 injections to the glabellar complex on Day 1. Participants meeting retreatment criteria may receive up to 2 additional doses of treatment during the study. Participants will attend regular visits during the study at a study site. The effect of the treatment will be checked by medical assessments, blood tests, telephone calls, questionnaires and checking for side effects.

Conditions

  • Glabellar Lines

Interventions

  • AGN-151586Drug

    Powder for Solution for Intramuscular Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse EventsTime frame: Day 1 (Baseline) to Day 126
  2. Participants With Post-Baseline Potentially Clinically Important (PCI) Values for Systolic Blood PressureTime frame: Day 1 (Baseline) to Day 126
  3. Participants With Post-Baseline PCI Values for Diastolic Blood PressureTime frame: Day 1 (Baseline) to Day 126
  4. Participants With Post-Baseline PCI Values for Heart RateTime frame: Day 1 (Baseline) to Day 126
  5. Participants With Post-baseline PCI Values in TemperatureTime frame: Day 1 (Baseline) to Day 126
  6. Participants With Post-baseline PCI Values in Electrocardiogram ParametersTime frame: Day 1 (Baseline) to Day 126
  7. Presence of Binding and Neutralizing Antidrug Antibodies to AGN-151586Time frame: Day 1 (Baseline) to Day 126

Locations

43 sites in 2 countries. Site status is shown where the registry gives one.

  • Skin Wellness Dermatology - Homewood /ID# 241233

    Birmingham, Alabama

  • Advanced Research Associates - Glendale /ID# 232245

    Glendale, Arizona

  • Skin Care and Laser Physicians of Beverly Hills /ID# 241237

    Los Angeles, California

  • The Eye Research Foundation /ID# 232229

    Newport Beach, California

  • Cosmetic Laser Dermatology /ID# 243513

    San Diego, California

  • UC San Diego Health - University Center Lane - La Jolla /ID# 241243

    San Diego, California

  • Ava T. Shamban MD - Santa Monica. /ID# 241246

    Santa Monica, California

  • Art of Skin MD /ID# 241244

    Solana Beach, California

  • Moradi MD /ID# 241242

    Vista, California

  • AboutSkin Research, LLC /ID# 241702

    Greenwood Village, Colorado

  • Susan H. Weinkle MD /ID# 233835

    Bradenton, Florida

  • Skin Research Institute LLC /ID# 232240

    Coral Gables, Florida

  • Skin and Cancer Associates, LLP /ID# 232228

    Miami, Florida

  • ForCare Clinical Research /ID# 241229

    Tampa, Florida

  • Hamilton Research, LLC /ID# 241232

    Alpharetta, Georgia

  • Atlanta Biomedical Clinical Research /ID# 241258

    Atlanta, Georgia

  • Meridian Clinical Research Dermatology /ID# 241234

    Savannah, Georgia

  • DeNova Research /ID# 232231

    Chicago, Illinois

  • Advanced Dermatology /ID# 241252

    Lincolnshire, Illinois

  • Laser and Skin Surgery Center of Indiana /ID# 233834

    Indianapolis, Indiana

  • Coleman Center For Cosmetic Dermatologic Surgery /ID# 232230

    Metairie, Louisiana

  • Etre Cosmetic Dermatology and Laser Center /ID# 232235

    New Orleans, Louisiana

  • Visage Dermatology and Aesthetic Center /ID# 241248

    Largo, Maryland

  • Rkmd, Llc /Id# 241239

    North Bethesda, Maryland

  • Michigan Center for Research Company /ID# 241255

    Clarkston, Michigan

  • Rao Dermatology /ID# 243515

    Atlantic Highlands, New Jersey

  • image Dermatology, P.C. /ID# 241227

    Montclair, New Jersey

  • The Rejuva Center /ID# 244285

    Latham, New York

  • Mariwalla Dermatology /ID# 241240

    West Islip, New York

  • Northwest Dermatology Institute /ID# 233498

    Portland, Oregon

  • Perelman Center for Advanced Medicine - /ID# 243966

    Philadelphia, Pennsylvania

  • Sherman Aesthetic Center /ID# 241247

    Nashville, Tennessee

  • Tennessee Clinical Research Center /ID# 241254

    Nashville, Tennessee

  • DermResearch, Inc. Austin, TX /ID# 241228

    Austin, Texas

  • Bellaire Dermatology Associates /ID# 232243

    Bellaire, Texas

  • J&S Studies, Inc. /ID# 241236

    College Station, Texas

  • Dallas Center for Dermatology and Aesthetics /ID# 241245

    Dallas, Texas

  • Swinyer-Woseth Dermatology /ID# 241250

    Salt Lake City, Utah

  • The Education & Research Foundation, Inc. /ID# 241225

    Lynchburg, Virginia

  • Premier Clinical Research /ID# 233836

    Spokane, Washington

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.